|
Date |
Milestone |
| 2010 |
Nycomed UK restructures to introduce a new flexible business model that allows it to invest more appropriately in therapeutic and geographical areas based on company and customer priorities |
| 2009 |
Nycomed UK outlicenses Daxas® (roflumilast) to MSD |
| 2009 |
Instanyl®q (intranasal fentanyl spray) launched |
| 2008 |
Nycomed UK restructures to become a speciality pharma company |
| 2007 |
Following the acquisition of Altana Pharma, the new integrated business relocates to Marlow |
| 2003 |
Nycomed UK Limited is established with its head office in Oxford |